NDA 019710 · Liebel-Flarsheim
Optiray 350
Ioversol · Injection · Radiographic Contrast Agent
NovelLast checked: Nov 21, 2026Latest source record: Apr 25, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1988
Dec 30, 1988
Approved uses
7
Original approval plus efficacy supplements
Registered trials
9
1 Phase 3, 2 recruiting
FAERS reports
3,856
2,888 serious, 236 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISKS WITH INADVERTENT INTRATHECAL ADMINISTRATION FOR INTRA-ARTERIAL AND INTRAVENOUS USE ONLY Inadvertent intrathecal administration may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. [see Warnings and Precautions ( 5.1 )] WARNING: RISKS WITH INADVERTENT INTRATHECAL ADMINISTRATION FOR INTRA-ARTERIAL AND INTRAVENOUS USE ONLY Inadvertent intrathecal administration may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. ( 5.1 )
What it is approved for
From the label in effect Feb 17, 2023.
OPTIRAY is indicated for: OPTIRAY is a radiographic contrast agent indicated for the following: Intra-arterial Procedures ( 1.1 ) Adults: Cerebral Arteriography (300, 320 mg iodine/mL) Peripheral Arteriography (300, 320, 350 mg iodine/mL ) Visceral and Renal Arteriography, Aortography (320 mg iodine/mL) Coronary Arteriography and Left Ventriculography (320, 350 mg iodine/mL) Pediatric Patients: Angiocardiography (320, 350 mg iodine/mL) Intravenous Procedures ( 1.2 ) Adults: Computed tomography (CT) Imaging of Head and Body (300, 320, 350 mg iodine/mL) Venography (300, 320, 350 mg iodine/mL) Intravenous Excretory Urography (300, 320, 350 mg iodine/mL) Intravenous Digital Subtraction Angiography (350 mg iodine/mL) Pediatric Patients: CT Imaging of the Head and Body, and Intravenous Excretory Urography (320 mg iodine/mL) 1.1 Intra-arterial In adults OPTIRAY 300: cerebral arteriography and peripheral arteriography. OPTIRAY 320: cerebral arteriography, peripheral arteriography, visceral and renal arteriography, aortography, coronary arteriography, and left ventriculography. OPTIRAY 350: peripheral arteriography coronary arteriography, and left ventriculography. In pediatric patients OPTIRAY 320 and OPTIRAY 350: angiocardiography. 1.2 Intra-venous In adults OPTIRAY 300: CT imaging of the head and body, venography, and intravenous excretory urography. OPTIRAY 320: CT imaging of the head and body, venography, and intravenous excretory urography. OPTIRAY 350: CT imaging of the head and body, venography, intravenous excretory urography, and intravenous digital subtraction angiography (IV-DSA). In pediatric patients OPTIRAY 320: CT imaging of the head and body, and intravenous excretory urography.
Mechanism: Intravascular injection of ioversol opacifies vessels in the path of the flow of the contrast medium, permitting visualization of the internal structures until significant hemodilution occurs. In imaging of the body, iodinated contrast agents diffuse from the vascular into the extravascular space. In normal brain with an intact blood-brain barrier, contrast does not diffuse into the extravascular space. In patients with a disrupted blood-brain barrier, contrast agent accumulates in the interstitial space in the region of disruption.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 21, 1995 Supplement 18 · Efficacy
- Jul 27, 1993 Supplement 17 · Efficacy
- Mar 9, 1993 Supplement 16 · Efficacy
- Dec 11, 1992 Supplement 12 · Efficacy
- Jul 9, 1992 Supplement 7 · Efficacy
- Jan 22, 1992 Supplement 4 · Efficacy
- Dec 30, 1988 Original approval · Type 1 - New Molecular Entity
5 products under this application
- OPTIRAY 350 · IOVERSOL 74% · INJECTABLE, INJECTION · Prescription
- OPTIRAY 160 · IOVERSOL 34% · INJECTABLE, INJECTION · Discontinued
- OPTIRAY 320 · IOVERSOL 68% · INJECTABLE, INJECTION · Prescription
- OPTIRAY 300 · IOVERSOL 64% · INJECTABLE, INJECTION · Prescription
- OPTIRAY 240 · IOVERSOL 51% · INJECTABLE, INJECTION · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Ioversol" as an intervention, any sponsor and status, largest first.
International Peace Maternity and Child Health HospitalAcademic, hospital or other
NCT06639152 · 1,187 participants · Start May 4, 2020 · Primary completion Aug 30, 2023
Drug: oil-based contrast medium; water-based contrast medium · For: Infertility
Sites: Shanghai, China
- Effect of Genicular Arteries Embolization in Symptomatic Knee Osteoarthritis LipioJoint-2Pivotal-lookingRecruiting
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT06497140 · 130 participants (planned) · Start Sep 30, 2024 · Primary completion Jan 1, 2028
Drug: Ethiodized Oil-based emulsion · For: Knee Osteoarthritis
Sites: Paris, France · 3 sites in all
- Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the LiverCompleted
Eastern Cooperative Oncology GroupResearch network
NCT00003907 · 50 participants · Start Dec 15, 1999 · Primary completion May 2011
Drug: cisplatin; doxorubicin and 1 more · For: Liver Cancer; Metastatic Cancer
Sites: Fort Collins, Colorado; Jacksonville, Florida; Atlanta, Georgia · 37 sites in all
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT04733092 · 22 participants · Start Mar 3, 2021 · Primary completion Jun 20, 2022
Drug: Lipiodol · For: Knee Osteoarthritis
Sites: Paris, France
Washington University School of MedicineAcademic, hospital or other
NCT02117115 · 21 participants · Start Jun 2014 · Primary completion Oct 2014
Drug: Ioversol · For: Myelodysplastic Syndromes; Leukemia, Myeloid, Acute; Leukemia, Myelogenous, Chronic and 1 more
Sites: St Louis, Missouri
University Hospital, GrenobleAcademic, hospital or other
NCT06611007 · 15 participants (planned) · Start Jan 30, 2025 · Primary completion Jul 15, 2028
Drug: embolization therapy · For: Osteoarthritis
Sites: Échirolles, France
GuerbetIndustry
NCT00793182 · 6 participants · Start Jan 2009 · Primary completion Jun 2009
Drug: Ioversol 320 mgI/mL; Iodixanol 320 mgI/mL · For: Renal Impairment
Sites: Birmingham, Alabama; Tucson, Arizona; Washington D.C., District of Columbia · 13 sites in all
GE HealthcareIndustry
NCT00335101 · 0 participants · Start Jun 2006
Drug: Iodixanol, Ioversol, Iopromide · For: Coronary Artery Disease (CAD); Renal Impairment; Diabetes Mellitus
Sites: Princeton, New Jersey; Munich, Germany
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- urticaria545
- dyspnoea465
- pruritus437
- rash243
- nausea217
- throat irritation215
- sneezing208
- erythema206
- nephropathy toxic200
- cough193
- anaphylactic shock176
- vomiting172
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 66 |
| 2005 | 78 |
| 2006 | 137 |
| 2007 | 146 |
| 2008 | 177 |
| 2009 | 378 |
| 2010 | 303 |
| 2011 | 314 |
| 2012 | 272 |
| 2013 | 293 |
| 2014 | 136 |
| 2015 | 88 |
| 2016 | 136 |
| 2017 | 170 |
| 2018 | 151 |
| 2019 | 159 |
| 2020 | 129 |
| 2021 | 153 |
| 2022 | 118 |
| 2023 | 88 |
| 2024 | 147 |
| 2025 | 115 |
| 2026 | 102 |
Recalls
1 FDA enforcement reports for this application.
Sep 13, 2019 · Class II · Terminated
Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Double-blind study of a new nonionic contrast agent for digital subtraction arteriography.
Weiss JP, McLean GK, Modic MT, et al. · Invest Radiol 1994 · Clinical Trial, Comparative Study
- A randomized double-blind trial of ioversol and iopamidol in contrast-enhanced computed body tomography.
Sage MR, Evill CA, Fon GT · Invest Radiol 1989 · Clinical Trial, Comparative Study
- [Usefulness of ioversol (MP-328) in angiocardiography--a multicenter comparative study with iopamidol].
Morimoto S, Kozuka T, Takamiya M, et al. · Nihon Igaku Hoshasen Gakkai Zasshi 1990 · Clinical Trial, Multicenter Study
- NGAL is an early predictive biomarker of contrast-induced nephropathy in children.
Hirsch R, Dent C, Pfriem H, et al. · Pediatr Nephrol 2007 · Clinical Trial, Research Support, N.I.H., Extramural
- Acute Adverse Reactions to Nonionic Iodinated Contrast Media: A Meta-Analysis.
Suh YJ, Yoon SH, Hong H, et al. · Invest Radiol 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Estimating the rate of acute adverse reactions to non-ionic low-osmolar contrast media: a systematic review and meta-analysis.
Wei Y, Jiang X, Hibberd M, et al. · Eur Radiol 2025 · Meta-Analysis, Systematic Review
Sponsor: Liebel-Flarsheim · Also marketed as Optiray 160, Optiray 320, Optiray 300, Optiray 240
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.